Top

Published in:

01-08-2018 | Report

AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report

Authors: Jan-Henrik Mikesch, Wolfgang Hartmann, Linus Angenendt, Otmar Huber, Christoph Schliemann, Maria Francisca Arteaga, Eva Wardelmann, Claudia Rudack, Wolfgang E. Berdel, Markus Stenner, Inga Grünewald

Published in: Cellular Oncology | Issue 4/2018

Abstract

Purpose

Salivary gland cancer (SGC) is a rare and heterogeneous disease with significant differences in recurrence and metastasis characteristics. As yet, little is known about the mechanisms underlying the initiation and/or progression of these diverse tumors. In recent years, the AAA+ ATPase family members Pontin (RuvBL1, Tip49a) and Reptin (RuvBL2, Tip49b) have been implicated in various processes, including transcription regulation, chromatin remodeling and DNA damage repair, that are frequently deregulated in cancer. The aim of this study was to assess the clinical and functional significance of Reptin and Pontin expression in SGC.

Methods

Immunohistochemical staining of Pontin, Reptin, β-catenin, Cyclin D1, TP53 and MIB-1 was performed on a collection of 94 SGC tumor samples comprising 13 different histological subtypes using tissue microarrays.

Results

We found that Reptin and Pontin were expressed in the majority of SGC samples across all histological subtypes. Patients with a high Reptin expression showed a significantly inferior 5-year overall survival rate compared to patients with a low Reptin expression (47.7% versus 78.3%; p = 0.033), whereas no such difference was observed for Pontin. A high Reptin expression strongly correlated with a high expression of the proliferation marker MIB-1 (p = 0.003), the cell cycle regulator Cyclin D1 (p = 0.006), accumulation of TP53 as a surrogate p53 mutation marker (p = 0.042) and cytoplasmic β-catenin expression (p = 0.002). Increased Pontin expression was found to significantly correlate with both cytoplasmic and nuclear β-catenin expression (p = 0.037 and p = 0.018, respectively), which is indicative for its oncogenic function.

Conclusions

Our results suggest a role of Reptin and Pontin in SGC tumor progression and/or patient survival. Therefore, SGC patients exhibiting a high Reptin expression may benefit from more aggressive therapeutic regimens. Future studies should clarify whether such patients may be considered for more radical surgery, extended adjuvant therapy and/or targeted therapy.

M. Guzzo, L.D. Locati, F.J. Prott, G. Gatta, M. McGurk, L. Licitra, Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74, 134–148 (2010). https://doi.org/10.1016/j.critrevonc.2009.10.004 CrossRefPubMed

R.J. Zarbo, Salivary gland neoplasia: A review for the practicing pathologist. Mod Pathol 15, 298–323 (2002). https://doi.org/10.1038/modpathol.3880525 CrossRefPubMed

A. Skalova, D.R. Gnepp, J.S. Lewis Jr., J.L. Hunt, J.A. Bishop, H. Hellquist, A. Rinaldo, V. Vander Poorten, A. Ferlito, Newly described entities in salivary gland pathology. Am J Surg Pathol 41, e33–e47 (2017). https://doi.org/10.1097/PAS.0000000000000883 CrossRefPubMed

A. Busch, L. Bauer, E. Wardelmann, C. Rudack, I. Grunewald, M. Stenner, Prognostic relevance of epithelial-mesenchymal transition and proliferation in surgically treated primary parotid gland cancer. J Clin Pathol 70, 403–409 (2017). https://doi.org/10.1136/jclinpath-2016-203745 CrossRefPubMed

I. Grunewald, M. Trautmann, A. Busch, L. Bauer, S. Huss, P. Schweinshaupt, C. Vollbrecht, M. Odenthal, A. Quaas, R. Buttner, M.F. Meyer, D. Beutner, K.B. Huttenbrink, E. Wardelmann, M. Stenner, W. Hartmann, MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas. Oncotarget 7, 75261–75272 (2016). https://doi.org/10.18632/oncotarget.12127 CrossRefPubMedPubMedCentral

I. Grunewald, C. Vollbrecht, J. Meinrath, M.F. Meyer, L.C. Heukamp, U. Drebber, A. Quaas, D. Beutner, K.B. Huttenbrink, E. Wardelmann, W. Hartmann, R. Buttner, M. Odenthal, M. Stenner, Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget 6, 18224–18237 (2015). https://doi.org/10.18632/oncotarget.4015 CrossRefPubMedPubMedCentral

G. Stenman, F. Persson, M.K. Andersson, Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol 50, 683–690 (2014). https://doi.org/10.1016/j.oraloncology.2014.04.008 CrossRefPubMed

J.G. Armstrong, L.B. Harrison, R.H. Spiro, D.E. Fass, E.W. Strong, Z.Y. Fuks, Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116, 290–293 (1990)CrossRefPubMed

S. Sood, M. McGurk, F. Vaz, Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130, S142–S149 (2016). https://doi.org/10.1017/S0022215116000566 CrossRefPubMedPubMedCentral

10.

E.S. Choi, S. Oh, B. Jang, H.J. Yu, J.A. Shin, N.P. Cho, I.H. Yang, D.H. Won, H.J. Kwon, S.D. Hong, S.D. Cho, Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. Cell Oncol 40, 235–246 (2017). https://doi.org/10.1007/s13402-017-0318-8 CrossRef

11.

P.M. Matias, S.H. Baek, T.M. Bandeiras, A. Dutta, W.A. Houry, O. Llorca, J. Rosenbaum, The AAA+ proteins Pontin and Reptin enter adult age: From understanding their basic biology to the identification of selective inhibitors. Front Mol Biosci 2, 17 (2015). https://doi.org/10.3389/fmolb.2015.00017 CrossRefPubMedPubMedCentral

12.

A. Grigoletto, P. Lestienne, J. Rosenbaum, The multifaceted proteins Reptin and Pontin as major players in cancer. Biochim Biophys Acta 1815, 147–157 (2011). https://doi.org/10.1016/j.bbcan.2010.11.002 PubMedCrossRef

13.

O. Huber, L. Menard, V. Haurie, A. Nicou, D. Taras, J. Rosenbaum, Pontin and reptin, two related ATPases with multiple roles in cancer. Cancer Res 68, 6873–6876 (2008). https://doi.org/10.1158/0008-5472.CAN-08-0547 CrossRefPubMed

14.

S. Jha, A. Dutta, RVB1/RVB2: Running rings around molecular biology. Mol Cell 34, 521–533 (2009). https://doi.org/10.1016/j.molcel.2009.05.016 CrossRefPubMedPubMedCentral

15.

M.L. Carlson, E.T. Wilson, S.M. Prescott, Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a. Mol Cancer 2, 42 (2003). https://doi.org/10.1186/1476-4598-2-42 CrossRefPubMedPubMedCentral

16.

M.M. Maslon, R. Hrstka, B. Vojtesek, T.R. Hupp, A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. J Mol Biol 404, 418–438 (2010). https://doi.org/10.1016/j.jmb.2010.09.035 CrossRefPubMed

17.

J.C. Lauscher, S. Elezkurtaj, S. Dullat, S. Lipka, J. Grone, H.J. Buhr, O. Huber, M. Kruschewski, Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma. Oncol Rep 28, 1619–1624 (2012). https://doi.org/10.3892/or.2012.1968 CrossRefPubMed

18.

J.C. Lauscher, C. Loddenkemper, L. Kosel, J. Grone, H.J. Buhr, O. Huber, Increased pontin expression in human colorectal cancer tissue. Hum Pathol 38, 978–985 (2007). https://doi.org/10.1016/j.humpath.2007.01.005 CrossRefPubMed

19.

J. Ren, W. Li, H. Liu, L. Yan, W. Jiao, D. Li, Y. Tang, G. Gu, Z. Xu, Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells. Urol Oncol 31, 1358–1366 (2013). https://doi.org/10.1016/j.urolonc.2012.01.004 CrossRefPubMed

20.

V. Haurie, L. Menard, A. Nicou, C. Touriol, P. Metzler, J. Fernandez, D. Taras, P. Lestienne, C. Balabaud, P. Bioulac-Sage, H. Prats, J. Zucman-Rossi, J. Rosenbaum, Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology 50, 1871–1883 (2009). https://doi.org/10.1002/hep.23215 CrossRefPubMedPubMedCentral

21.

O. Breig, S. Bras, N. Martinez Soria, D. Osman, O. Heidenreich, M. Haenlin, L. Waltzer, Pontin is a critical regulator for AML1-ETO-induced leukemia. Leukemia 28, 1271–1279 (2014). https://doi.org/10.1038/leu.2013.376 CrossRefPubMed

22.

J. Elkaim, M. Castroviejo, D. Bennani, S. Taouji, N. Allain, M. Laguerre, J. Rosenbaum, J. Dessolin, P. Lestienne, First identification of small-molecule inhibitors of Pontin by combining virtual screening and enzymatic assay. Biochem J 443, 549–559 (2012). https://doi.org/10.1042/BJ20111779 CrossRefPubMed

23.

A. Bauer, O. Huber, R. Kemler, Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proc Natl Acad Sci U S A 95, 14787–14792 (1998)CrossRefPubMedPubMedCentral

24.

A. Bauer, S. Chauvet, O. Huber, F. Usseglio, U. Rothbacher, D. Aragnol, R. Kemler, J. Pradel, Pontin52 and reptin52 function as antagonistic regulators of beta-catenin signalling activity. EMBO J 19, 6121–6130 (2000). https://doi.org/10.1093/emboj/19.22.6121 CrossRefPubMedPubMedCentral

25.

O. Tetsu, F. McCormick, Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–426 (1999). https://doi.org/10.1038/18884 CrossRefPubMed

26.

A. Skalova, T. Vanecek, R. Sima, J. Laco, I. Weinreb, B. Perez-Ordonez, I. Starek, M. Geierova, R.H. Simpson, F. Passador-Santos, A. Ryska, I. Leivo, Z. Kinkor, M. Michal, Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34, 599–608 (2010). https://doi.org/10.1097/PAS.0b013e3181d9efcc PubMedCrossRef

27.

N. Friedrichs, L. Kriegl, C. Poremba, K.L. Schaefer, H.E. Gabbert, A. Shimomura, E. Paggen, S. Merkelbach-Bruse, R. Buettner, Pitfalls in the detection of t(11;22) translocation by fluorescence in situ hybridization and RT-PCR: A single-blinded study. Diagn Mol Pathol 15, 83–89 (2006)CrossRefPubMed

28.

H.U. Schildhaus, L.C. Heukamp, S. Merkelbach-Bruse, K. Riesner, K. Schmitz, E. Binot, E. Paggen, K. Albus, W. Schulte, Y.D. Ko, A. Schlesinger, S. Ansen, W. Engel-Riedel, M. Brockmann, M. Serke, U. Gerigk, S. Huss, F. Goke, S. Perner, K. Hekmat, K.F. Frank, M. Reiser, R. Schnell, M. Bos, C. Mattonet, M. Sos, E. Stoelben, J. Wolf, T. Zander, R. Buettner, Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 25, 1473–1480 (2012). https://doi.org/10.1038/modpathol.2012.102 CrossRefPubMedPubMedCentral

29.

J. Weiske, O. Huber, The histidine triad protein Hint1 interacts with Pontin and Reptin and inhibits TCF-beta-catenin-mediated transcription. J Cell Sci 118, 3117–3129 (2005). https://doi.org/10.1242/jcs.02437 CrossRefPubMed

30.

J.H. Kim, B. Kim, L. Cai, H.J. Choi, K.A. Ohgi, C. Tran, C. Chen, C.H. Chung, O. Huber, D.W. Rose, C.L. Sawyers, M.G. Rosenfeld, S.H. Baek, Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434, 921–926 (2005). https://doi.org/10.1038/nature03452 CrossRefPubMed

31.

L. Menard, D. Taras, A. Grigoletto, V. Haurie, A. Nicou, N. Dugot-Senant, P. Costet, B. Rousseau, J. Rosenbaum, In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence. J Hepatol 52, 681–689 (2010). https://doi.org/10.1016/j.jhep.2009.12.029 CrossRefPubMed

32.

X. Zhang, J. Ren, L. Yan, Y. Tang, W. Zhang, D. Li, Y. Zang, F. Kong, Z. Xu, Cytoplasmic expression of pontin in renal cell carcinoma correlates with tumor invasion, metastasis and patients' survival. PLoS One 10, e0118659 (2015). https://doi.org/10.1371/journal.pone.0118659 CrossRefPubMedPubMedCentral

33.

M.V. Suzzi, A. Alessi, C. Bertarelli, A. Cancellieri, L. Procaccio, D. Dall'olio, P. Laudadio, Prognostic relevance of cell proliferation in major salivary gland carcinomas. Acta Otorhinolaryngol Ital 25, 161–168 (2005)PubMed

34.

C.J. Gottardi, E. Wong, B.M. Gumbiner, E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 153, 1049–1060 (2001)CrossRefPubMedPubMedCentral

35.

C.J. Gottardi, B.M. Gumbiner, Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol 167, 339–349 (2004). https://doi.org/10.1083/jcb.200402153 CrossRefPubMedPubMedCentral

36.

W. Rottbauer, A.J. Saurin, H. Lickert, X. Shen, C.G. Burns, Z.G. Wo, R. Kemler, R. Kingston, C. Wu, M. Fishman, Reptin and pontin antagonistically regulate heart growth in zebrafish embryos. Cell 111, 661–672 (2002)CrossRefPubMed

Title: AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report
Authors: Jan-Henrik Mikesch
Wolfgang Hartmann
Linus Angenendt
Otmar Huber
Christoph Schliemann
Maria Francisca Arteaga
Eva Wardelmann
Claudia Rudack
Wolfgang E. Berdel
Markus Stenner
Inga Grünewald
Publication date: 01-08-2018
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 4/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-018-0382-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma

Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining

Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells

Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis

Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance

Patched-2 functions to limit Patched-1 deficient skin cancer growth

Keynote webinar | Spotlight on antibody–drug conjugates in cancer